[ad_1] SHANGHAI, Oct. 19, 2025 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced […]

[ad_1] — Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) — — RSV neutralizing antibodies for Clover’s non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted AREXVY in […]